-

Shareholder Alert: Robbins LLP Announces Deutsche Bank Aktiengesellschaft (DB) Accused of Misleading Shareholders

SAN DIEGO & FRANKFURT, Germany--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Deutsche Bank Aktiengesellschaft (NYSE: DB) filed a class action complaint against the Bank for alleged violations of the Securities Exchange Act of 1934 between November 7, 2017 and July 6, 2020. Deutsche Bank provides investment, financial, and related products and services to private individuals, corporate entities, and institutional clients worldwide.

If you suffered a loss as a result of Deutsche Bank's misconduct, click here.

Deutsche Bank Aktiengesellschaft (DB) Accused of Misleading Shareholders

According to the complaint, in March 2018 after years of scandal, Deutsche Bank touted its remediation efforts regarding its anti-money laundering ("AML") and other control functions in its annual report for 2017, stating that the Bank "[has] identified the need to strengthen [the Bank’s] internal control environment and infrastructure and have embarked on initiatives to accomplish this.” Throughout the relevant period, the Bank represented that it was continuing to conduct these initiatives and reaffirmed its efforts at remediating AML and other control functions. Despite the positive representations of the Bank's efforts, on May 13, 2020, media outlets reported that the Federal Reserve's internal audit had revealed the Bank had failed to address concerns that had been identified years earlier, including its AML and other control procedure failures. Finally, on July 7, 2020, the New York State Department of Financial Services fined the Bank $150 million for neglecting to flag numerous questionable transactions from accounts associated with convicted sex offender Jeffrey Epstein and two correspondent banks, Danske Estonia and FBME Bank, both of which were subjects of prior scandals involving financial misconduct.

Deutsche Bank Aktiengesellschaft (DB) Shareholders Have Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Deutsche Bank settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the FS KKR Capital Corp. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired FS KKR Capital (NYSE: FSK) securities between May 8, 2024 and February 25, 2026. FS KKR Capital is a private credit firm, also known as Business Development Company, which specializes in making private loans to companies.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Ro...

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...
Back to Newsroom